195 related articles for article (PubMed ID: 27993090)
1. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.
Koido S; Okamoto M; Shimodaira S; Sugiyama H
Immunotherapy; 2016 Nov; 8(11):1309-1320. PubMed ID: 27993090
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines.
Hanada S; Tsuruta T; Haraguchi K; Okamoto M; Sugiyama H; Koido S
Hum Vaccin Immunother; 2019; 15(2):397-406. PubMed ID: 30230959
[TBL] [Abstract][Full Text] [Related]
3. Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer.
Koido S; Okamoto M; Kobayashi M; Shimodaira S; Sugiyama H
Discov Med; 2017 Aug; 24(130):41-49. PubMed ID: 28950074
[TBL] [Abstract][Full Text] [Related]
4. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
[TBL] [Abstract][Full Text] [Related]
5. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1.
Ito Z; Kan S; Bito T; Horiuchi S; Akasu T; Yoshida S; Kajihara M; Hokari A; Saruta M; Yoshida N; Kobayashi M; Ohkusa T; Shimodaira S; Okamoto M; Sugiyama H; Koido S
Oncology; 2019; 97(3):135-148. PubMed ID: 31216557
[TBL] [Abstract][Full Text] [Related]
6. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
Katsuda M; Miyazawa M; Ojima T; Katanuma A; Hakamada K; Sudo K; Asahara S; Endo I; Ueno M; Hara K; Yamada S; Fujii T; Satoi S; Ioka T; Ohira M; Akahori T; Kitano M; Nagano H; Furukawa M; Adachi T; Yamaue H
Trials; 2019 Apr; 20(1):242. PubMed ID: 31029154
[TBL] [Abstract][Full Text] [Related]
7. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
Kajihara M; Takakura K; Kanai T; Ito Z; Matsumoto Y; Shimodaira S; Okamoto M; Ohkusa T; Koido S
World J Gastroenterol; 2016 May; 22(18):4446-58. PubMed ID: 27182156
[TBL] [Abstract][Full Text] [Related]
8. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
Van Tendeloo VF; Van de Velde A; Van Driessche A; Cools N; Anguille S; Ladell K; Gostick E; Vermeulen K; Pieters K; Nijs G; Stein B; Smits EL; Schroyens WA; Gadisseur AP; Vrelust I; Jorens PG; Goossens H; de Vries IJ; Price DA; Oji Y; Oka Y; Sugiyama H; Berneman ZN
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13824-9. PubMed ID: 20631300
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.
Tsukinaga S; Kajihara M; Takakura K; Ito Z; Kanai T; Saito K; Takami S; Kobayashi H; Matsumoto Y; Odahara S; Uchiyama K; Arakawa H; Okamoto M; Sugiyama H; Sumiyama K; Ohkusa T; Koido S
World J Gastroenterol; 2015 Oct; 21(39):11168-78. PubMed ID: 26494971
[TBL] [Abstract][Full Text] [Related]
10. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
[TBL] [Abstract][Full Text] [Related]
11. Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.
Takakura K; Koido S; Kan S; Yoshida K; Mori M; Hirano Y; Ito Z; Kobayashi H; Takami S; Matsumoto Y; Kajihara M; Misawa T; Okamoto M; Sugiyama H; Homma S; Ohkusa T; Tajiri H
Anticancer Res; 2015 Jan; 35(1):555-62. PubMed ID: 25550602
[TBL] [Abstract][Full Text] [Related]
12. Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial.
Nagai K; Adachi T; Harada H; Eguchi S; Sugiyama H; Miyazaki Y
Anticancer Res; 2020 Oct; 40(10):5765-5776. PubMed ID: 32988904
[TBL] [Abstract][Full Text] [Related]
13. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.
Osada T; Woo CY; McKinney M; Yang XY; Lei G; Labreche HG; Hartman ZC; Niedzwiecki D; Chao N; Amalfitano A; Morse MA; Lyerly HK; Clay TM
Clin Cancer Res; 2009 Apr; 15(8):2789-96. PubMed ID: 19351755
[TBL] [Abstract][Full Text] [Related]
14. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
[TBL] [Abstract][Full Text] [Related]
15. [WT1-targeting cancer vaccine].
Sugiyama H
Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381
[TBL] [Abstract][Full Text] [Related]
16. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.
Van Driessche A; Berneman ZN; Van Tendeloo VF
Oncologist; 2012; 17(2):250-9. PubMed ID: 22291091
[TBL] [Abstract][Full Text] [Related]
17. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.
Yanagisawa R; Koizumi T; Koya T; Sano K; Koido S; Nagai K; Kobayashi M; Okamoto M; Sugiyama H; Shimodaira S
Anticancer Res; 2018 Apr; 38(4):2217-2225. PubMed ID: 29599342
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
[TBL] [Abstract][Full Text] [Related]
19. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.
Walters JN; Ferraro B; Duperret EK; Kraynyak KA; Chu J; Saint-Fleur A; Yan J; Levitsky H; Khan AS; Sardesai NY; Weiner DB
Mol Ther; 2017 Apr; 25(4):976-988. PubMed ID: 28237837
[TBL] [Abstract][Full Text] [Related]
20. Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives.
Ogasawara M
Hum Vaccin Immunother; 2024 Dec; 20(1):2296735. PubMed ID: 38148629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
